Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Appendix B: Drug Characteristics Tables
Characteristics of the Fusion Inhibitor
Last Updated: December 18, 2019; Last Reviewed: December 18, 2019
|Formulation||Dosing Recommendation||Serum Half-Life||Elimination||Adverse Eventsa|
||3.8 hours||Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool||
Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients
Increased incidence of bacterial pneumonia
HSR occurs in <1% of patients. Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.
|a Also see Table 17.
Key: HSR = hypersensitivity reaction; SQ = subcutaneous; T-20 = enfuvirtide